Melanoma Central

Approximately half of patients with metastatic melanoma have BRAF mutations, specifically BRAF V600E and BRAF V600K mutations, that enable tumor cells to grow out of control. Continuous dosing with a combination of BRAF and MEK inhibitors has shown better results than intermittent dosing in these cases, according to recent research, while combination regimens also show promise.

Dermatology practices required evolution and adaptation as the COVID-19 pandemic struck the United States. One of the ways the specialty has been able to continue serving patients was via implementation of comprehensive telemedicine programs.